$NNOX

Nano-X Imaging faces March 29, 2027 Nasdaq deadline

Nano-X Imaging (NNOX) received a Nasdaq notice that its shares no longer meet the minimum bid-price requirement of $1.00. The company has until March 29, 2027, to regain compliance, with a potential 180-day extension if it transfers to Nasdaq Capital Market. NNOX is considering options to meet the requirement.

Original reporting
Published Oct 2, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 12:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NNOX
Bearish
medium confidence
Mentioned
$NNOX
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$NNOXBearishMed
01

Why it matters

The notice signals heightened risk for shareholders and may trigger short‑selling activity.

02

Market read

Regulatory compliance risk for a micro‑cap listed on Nasdaq; potential price volatility ahead of the deadline.

03

What to watch

Potential for a 180‑day extension if the company moves to the Capital Market, and any undisclosed share‑buyback plans that could lift the price.

Relevance 6/10Novelty 6/10Timing: deadline March 29, 2027

Background

Nasdaq requires listed companies to maintain a minimum $1.00 closing bid price for at least 10 consecutive trading days. Failure triggers a delisting notice and a compliance deadline.

Company-level read

Ticker impact

$NNOXBearishMedium confidence
Context

Nasdaq notified Nano-X Imaging that its shares fell below the $1.00 bid-price requirement and set a compliance deadline of March 29, 2027.

Expected impact

downward pressure as investors price in potential delisting risk

Evidence & confidence

Bid-price non‑compliance is a material regulatory issue for a micro‑cap; no remedial action has been announced.

Market effects

May affect other low‑price Nasdaq‑listed biotech and imaging firms facing similar compliance thresholds.

Limited to U.S. listed micro‑caps; no broader regional effect.

Minimal global impact; primarily a company‑specific regulatory issue.

Counterpoint

If Nano‑X can secure a capital raise or transfer to Nasdaq Capital Market, the compliance deadline could be a catalyst for a short‑term rally.

Key entities

  • Nano‑X Imaging Ltd.

    US‑listed imaging technology firm facing bid‑price compliance issue.

  • Nasdaq

    Regulatory body issuing the compliance notice.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.

$HAEMedAI 8/10

Haemonetics says FDA clears vascular closure device

Haemonetics announced FDA approval for its PerQseal Elite device, which seals arterial openings in heart and vascular procedures. The company acquired the technology via its 2026 purchase of Vivasure Medical. Shares rose 1.2% in extended trading. Additional clinical data will be presented at an upcoming conference.